Company Profile
Xencor Stock Price, News & Catalysts
- Ticker:
- XNCR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
29.00 USD (+4.30%)
Close
Last updated: August 24, 2026
831M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, XNCR closed up 4.30% at $29.00. No new same-company headline was identified in the current news window.
Company overview
Business overview
Xencor is a biotechnology company built around antibody engineering and next-generation immunology and oncology programs. Its platform approach gives it optionality across multiple therapeutic areas.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Xencor sits in specialty biotechnology.
Business Model Characteristics
The business blends partnered programs, internal development, and platform science, with valuation tied to data quality and collaboration economics.
Position Within the Biotechnology Landscape
Xencor is a platform antibody name that can re-rate quickly when clinical data or partner progress strengthens confidence in the platform.
Future catalysts
- Xencor's catalysts are XmAb platform updates, including vudalimab and other bispecific programs that can still create partnered or internal value. The company needs data that show the platform keeps producing.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xencor (XNCR)?
Xencor (XNCR) most recently closed at 29.00 USD, a +4.30% move versus the previous session.
What is the market cap of Xencor (XNCR)?
Xencor currently has a market capitalization of 831M USD on BioPharmSignal.
What does Xencor do?
Xencor is a biotechnology company built around antibody engineering and next-generation immunology and oncology programs. Its platform approach gives it optionality across multiple therapeutic areas.
On which exchange is XNCR stock listed?
Xencor (XNCR) is associated with NASDAQ, United States, Biopharma.
What is vudalimab?
Xencor's catalysts are XmAb platform updates, including vudalimab and other bispecific programs that can still create partnered or internal value.
Which conditions is Xencor targeting with vudalimab?
Xencor is associated with oncology, immunology based on its company overview and current catalyst commentary.
How does Xencor describe recent progress with vudalimab?
Xencor's catalysts are XmAb platform updates, including vudalimab and other bispecific programs that can still create partnered or internal value.
What is Xencor?
Xencor is a biotechnology company built around antibody engineering and next-generation immunology and oncology programs.